Breaking News Bar

Business News and Information

Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018

SAN DIEGO, March 7, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company's business at the 30th Annual ROTH Conference on Tuesday, March 13th, 2018 at 9:00 a.m. PT in the Blue – Salon 2 room at The Ritz Carlton, Laguna Niguel in Dana Point, CA.  The presentation will be broadcast via a live webcast and an archive of the presentation will be available for 365 days following the event.  The webcast can be accessed at  The Investor Relations section of the Imprimis website will have a link to the webcast as well, which can be found by clicking here.  Mark and Chief Financial Officer, Andrew Boll, will be hosting one-on-one meetings at the conference and attendees can contact their ROTH representative to arrange a meeting.

Imprimis Pharmaceuticals Logo (PRNewsFoto/Imprimis Pharmaceuticals)


Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is dedicated to making high quality innovative medications accessible and affordable in all 50 states.  The company's flexible business model allows a drug to be compounded or developed as an FDA-approved product through one of its subsidiaries or spin-out companies.  For more information about Imprimis, please visit the corporate website at


This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


Investor Contact:
Jon Patton


Cision View original content with multimedia:

SOURCE Imprimis Pharmaceuticals, Inc.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear